Boundless Bio, Inc.
BOLDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBoundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. With a market capitalization of $55.7M, it sits in micro-cap territory. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Market Cap
$55.7M
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
-2.67
EPS (TTM)
$-2.52
EPS (Fwd)
$-0.93
ROE
-50.2%
ROA
-22.8%
Cash
$92.8M
Total Debt
$48.3M
Free CF
-$30.9M
52W Change
108.4%
Annual Financials
Cash vs Debt
Where BOLD stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, BOLD finished 75.71% above its 150-day moving average ($1.40) and 79.56% above its 200-day moving average ($1.37). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BOLD overbought or oversold?
At the July 15, 2026 close, BOLD's RSI(14) was 38.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $92.8M in cash and $48.3M in debt, BOLD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$30.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -50.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
BOLD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BOLD.